Medpace Holdings, Inc.MEDP

時価総額
$166.3億
PER
臨床開発受託(CRO)の世界的最大手。フェーズI–IVのフルサービスと中央検査・バイオ分析ラボを展開。2024年に株式買戻しで527,160株、1.742億ドルの実施。約5,900人で北米・欧州・アジア44カ国展開。
2016年
12月31日
2017年
12月31日
2018年
12月31日
2019年
12月31日
2020年
12月31日
2021年
12月31日
2022年
12月31日
2023年
12月31日
2024年
12月31日
Cash and cash equivalents37262313227846128245669
Receivables, Net, Current8083133156161186253298296
Prepaid Expense and Other Assets, Current162021293543525063
Total current assets1331301783174746913345941,029
Property and equipment, net444952478593110121124
Operating lease right-of-use assets---52114130139145129
Goodwill661661661662662662662662662
Intangible assets, net1369969544641383634
Deferred income taxes----1254874100
Other assets5679917212522
Total assets9799519681,1431,3911,6601,3521,6572,101
Accounts Payable, Current111717222726333233
Accrued expenses242487109134159210293308
Contract with Customer, Liability, Current--148192256345463560711
Other current liabilities355192428484054
Total current liabilities1691932573434405578039251,105
Operating lease liabilities---45115131139142126
Deferred income tax liability----141122
Other long-term liabilities81113161618232843
Total liabilities3684473784175857079661,0981,275
Commitments and Contingencies---------
Preferred Stock, Value, Issued---------
Common Stock, Value, Issued000000000
Treasury stock - 70,073 and 70,573 shares at December 31, 2024 and 2023, respectively-------1212
Additional paid-in capital-630639667696728771803844
Retained earnings (accumulated deficit)-10-120-4168115235-360-2228
Accumulated other comprehensive loss-4-1-3-3-0-5-12-10-15
Total shareholders’ equity611504590726806953386559826
Total liabilities and shareholders’ equity9799519681,1431,3911,6601,3521,6572,101